Harvard Bioscience Inc

Harvard Bioscience Inc

HBIO Stock Report Card





Score: 100/100


HBIO returned 58.94% in the last 12 months. Based on the other stocks in its sector with an average return of -5.70%, its performance is above average giving it a grade of 100 of 100.


Score: 92/100


3 analysts offer 12-month price forecasts for HBIO. Together, they have an average target of 0, the most optimistic forecast put HBIO at 0 within 12-months and the most pessimistic has HBIO at 0.


Score: 72/100


HBIO had a bullish sentiment score of 72.09% across Twitter and StockTwits over the last 12 months. It had an average of 3.68 posts, 0.12 comments, and 0.46 likes per day.


Score: 79/100


HBIO receives a 78 of 100 based on 14 indicators. 10 are bullish, 2 are bearish.


Score: 10/100


HBIO has missed earnings 8 times in the last 20 quarters.


Score: 22/100


Out of the last 20 quarters, HBIO has had 5 profitable quarters and has increased their profits year over year on 3 of them.


Score: 53/100


HBIO has had a higher than average amount of volatility over the last 12 months giving it a grade of 53 of 100.

Harvard Bioscience Inc Summary

Nasdaq / HBIO
Medical Instruments & Supplies
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development in the United States and internationally. The company offers cellular and molecular technology instruments, such as syringe and peristaltic pump products, as well as a range of instruments and accessories for tissue and organ-based lab research, including surgical products, infusion systems, and behavior research systems; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, and electroporation and electrofusion instruments. It also engages in the development and manufacture of precision scientific measuring instrumentation and equipment, which cover data acquisition systems with custom amplifier configurations for cellular analysis, micro electrode array solutions for in vivo recordings, and vitro-systems for extracellular recordings; and offers preclinical products. The company markets its products through sales organizations, websites, catalogs, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories, as well as to contract research organizations, academic labs, and government researchers. It primarily sells its products under Harvard Apparatus, DSI, Ponemah, Buxco, Biochrom, BTX, and MCS brand names. The company was founded in 1901 and is headquartered in Holliston, Massachusetts.
pluto logo
Los Angeles, CA

Pluto is not a broker-dealer, investment adviser or member of FINRA. Securities offered by Alpaca Securities LLC (“Alpaca Securities”). Alpaca Securities is a member of FINRA and the Securities Investor Protection Corporation.

Alpaca Securities, LLC (“Alpaca Securities”) is not responsible for and is not providing the technology and services you receive from us to access and manage your brokerage account with Alpaca Securities. You firmly agree to hold Alpaca and its affiliates, owners, directors, employees, clearing firm and agents harmless for any loss or damage arising from the use of or unavailability of the technology and services that we are providing.

The content on this website is for informational purposes only. Pluto does not recommend any specific securities or investment strategies. Investing involves risk & investments may lose value, including the loss of principal. Past performance does not guarantee future results. Investors should consider their investment objectives and risks carefully before investing.